Back to All Combinations

MSI-H + BRAF WT

Intermediate Prognosis
5.00% Prevalence A General
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
MSI-H BRAF Wild-type
Recommended Treatments
Pembrolizumab first-line
Nivolumab + Ipilimumab
Treatments to Avoid

No specific contraindications noted

Key Statistics
5.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Excellent prognosis with immunotherapy. BRAF wild-type MSI-H has best outcomes.
Information

Category: General

Evidence Level: A

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.